Allergy Therapeutics PLC Allergy to host KOL webinar on VLP Peanut
September 07 2021 - 2:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
07 September 2021
Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")
Allergy Therapeutics to host KOL webinar on VLP Peanut vaccine
candidate
7 September 2021 Allergy Therapeutics (AIM: AGY), the fully
integrated commercial biotechnology pharmaceutical company
specialising in allergy vaccines, today announces that it will host
a webinar entitled 'VLP Peanut; a next generation peanut allergy
immunotherapy', on Friday 17 September 2021 at 14.00 BST, 09.00
EDT.
The webinar will include an introduction from Manuel Llobet,
Chief Executive Officer at Allergy Therapeutics, and a feature
presentation by key opinion leader (KOL), Dr. Mo Shamji, Reader in
Immunology & Allergy at Imperial College London.
Dr. Shamji will summarise the findings of the Group's ex vivo
VLP Peanut 001 biomarker study which, as announced on 3 August
2021, showed the hypoallergenic potential of the vaccine candidate,
due to enter the clinic in Q1 2022.
Dr. Matt Heath, Principal Scientist at Allergy Therapeutics,
will also provide an overview presentation on the Group's novel
virus-like particle (VLP) technology.
The presentation will be followed by a live Q&A session and
details can be accessed on the Group's website at
https://www.allergytherapeutics.com/investors/results-reports-and-presentations/
. A replay of both will be made available on the website shortly
after the event.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Carina Jurs
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development includes vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Adjuvant systems to boost performance of vaccines outside allergy
are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved over 9% compound annual
growth since formation, employs c.600 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUNVKRASUKRAR
(END) Dow Jones Newswires
September 07, 2021 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024